

Part I

Rs. in lacs

	Particulars	Quarter ended			Year to date Ended		RS. in lacs
		31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	Year Ended
		(Unaudited)			(Unaudited)		(Audited)
1	Income from operations						
a	Net sales / income from operations	11,402.17	10,474.51	9,204.46	32,126.01	28,877.29	39,539.68
	(inclusive of excise duty) - refer note no. 3						
b	Other operating income	192.04	188.17	136.46	546.32	312.09	475.76
	Total income from operations (net)	11,594.21	10,662.68	9,340.92	32,672.33	29,189.38	40,015.44
2	Expenses						
a	Cost of materials consumed	3,691.69	3,229.89	3,045.00	10,486.63	9,967.07	13,177.29
b	Purchases of stock-in-trade	162.34	136.05	210.07	470.29	521.90	676.13
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(210.03)	(165.45)	(156.07)	(629.41)	(65.47)	200.25
d	Excise Duty on Sales	202.70	153.49	145.75	502.85	417.65	567.60
e	Employee benefits expense	2,118.61	2,015.52	1,758.29	6,123.27	5,045.29	6,899.23
f	Depreciation and amortisation expense	588.02	552.07	497.19	1,673.18	1,509.69	2,018.79
g	Other expenses	3,026.23	2,996.52	2,376.39	8,505.34	7,471.54	10,048.79
	Total expenses	9,579.56	8,918.09	7,876.61	27,132.15	24,867.66	33,588.08
3	Profit from operations before other income, finance costs and exceptional items (1-2)	2,014.65	1,744.59	1,464.30	5,540.18	4,321.71	6,427.36
4	Other income	289.23	219.61	173.99	712.04	644.24	838.50
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	2,303.88	1,964.20	1,638.29	6,252.22	4,965.96	7,265.86
6	Finance costs	197.60	160.13	220.04	545.36	572.79	778.24
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	2,106.28	1,804.07	1,418.26	5,706.86	4,393.17	6,487.62
8	Exceptional items	-	-	-	-	-	-
9	Profit from ordinary activities before tax (7 + 8)	2,106.28	1,804.07	1,418.26	5,706.86	4,393.17	6,487.62
10	Tax expense	602.76	561.47	364.66	1,694.36	1,102.98	1,756.87
11	Net Profit from ordinary activities after tax (9 - 10)	1,503.52	1,242.60	1,053.59	4,012.50	3,290.19	4,730.75
12	Extraordinary items	-	-	-	-	-	-
13	Net Profit for the period (11 + 12)	1,503.52	1,242.60	1,053.59	4,012.50	3,290.19	4,730.75
14	Paid-up equity share capital (Face Value of ₹ 5 each)	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						20,177.89
16	Earnings per share (before extraordinary items) (not annualised)						
	Basic (Rs.)	3.41	2.82	2.39	9.10	7.46	10.72
	Diluted (Rs.)	3.41	2.82	2.39	9.10	7.46	10.72


Unaudited

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 6th February 2017.
- 2 The Board of Directors of the Company have declared interim dividend of Re. 1 per equity share having face value of Rs. 5 each .
- 3 The Board of Directors have recommended Bonus of 1:1 on existing paid up Equity Share Capital of the company subject to approval of the Shareholders.
- 4 The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- 5 Revenue from operations for the quarter ended 31st December 2016 and for all comparable periods / year ended 31st March 2016 is grossed up with the amount of excise duty on sales and the same is being shown as part of expenditure in accordance with SEBI clarification dated 20th September 2016.
- 6 The statutory Auditors have carried out the limited review of the above results.
- 7 The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

Place : New Delhi

Date : 06.02.2017



By order of the Board

Himanshu Baid

Managing Director



DOOGAR & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT

The Board of Directors

Poly Medicure Limited
232B, 3rd Floor, Okhla Industrial Estate,
Phase III, New Delhi – 110 020.

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicure Limited (the 'Company') for the quarter ended December 31st, 2016. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initiated by us for identification purposes. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the "Listing Regulations, 2015", including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of signature: New Delhi
Date of signature: 06.02.2017.

For Doogar & Associates
Chartered Accountants
Reg. No. 1061N
New Delhi

(M. S. Aggarwal)
Partner
M. No. 86580